These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
270 related articles for article (PubMed ID: 29512164)
1. Maternal red blood cell alloimmunization requiring intrauterine transfusion: a comparative study on management and outcome depending on the type of antibody. Phung TV; Houfflin-Debarge V; Ramdane N; Ghesquière L; Delsalle A; Coulon C; Subtil D; Vaast P; Garabedian C Transfusion; 2018 May; 58(5):1199-1205. PubMed ID: 29512164 [TBL] [Abstract][Full Text] [Related]
2. Outcome predictors for maternal red blood cell alloimmunisation with anti-K and anti-D managed with intrauterine blood transfusion. Vlachodimitropoulou E; Garbowski M; Anne Solomon S; Abbasi N; Seaward G; Windrim R; Keunen J; Kelly E; Van Mieghem T; Shehata N; Ryan G Br J Haematol; 2022 Feb; 196(4):1096-1104. PubMed ID: 34862601 [TBL] [Abstract][Full Text] [Related]
3. Relationship between maternal antibody type and antenatal course following intrauterine transfusion for red cell alloimmunisation. Walsh CA; Russell N; McAuliffe FM; Higgins S; Mahony R; Carroll S; McParland P Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):235-9. PubMed ID: 24075591 [TBL] [Abstract][Full Text] [Related]
4. Fetal middle cerebral artery Doppler to time intrauterine transfusion in red-cell alloimmunization: a randomized trial. Dodd JM; Andersen C; Dickinson JE; Louise J; Deussen A; Grivell RM; Voto L; Kilby MD; Windrim R; Ryan G; Ultrasound Obstet Gynecol; 2018 Mar; 51(3):306-312. PubMed ID: 28700818 [TBL] [Abstract][Full Text] [Related]
6. High additional maternal red cell alloimmunization after Rhesus- and K-matched intrauterine intravascular transfusions for hemolytic disease of the fetus. Schonewille H; Klumper FJ; van de Watering LM; Kanhai HH; Brand A Am J Obstet Gynecol; 2007 Feb; 196(2):143.e1-6. PubMed ID: 17306657 [TBL] [Abstract][Full Text] [Related]
7. [Follow-up of pregnancies with red-cell allo-immunisation: State-of-the art]. Carbonne B; Castaigne V; Cynober E; Levy R; Cortey A; Mailloux A; Larsen M; Brossard Y Gynecol Obstet Fertil; 2010 Mar; 38(3):205-13. PubMed ID: 20207183 [TBL] [Abstract][Full Text] [Related]
8. Maternal ABO-mismatched blood for intrauterine transfusion of severe hemolytic disease of the newborn due to anti-Rh17. Denomme GA; Ryan G; Seaward PG; Kelly EN; Fernandes BJ Transfusion; 2004 Sep; 44(9):1357-60. PubMed ID: 15318861 [TBL] [Abstract][Full Text] [Related]
9. Relationship between obstetric history and Rh(D) alloimmunization severity. Lobato G; Soncini CS Arch Gynecol Obstet; 2008 Mar; 277(3):245-8. PubMed ID: 17763861 [TBL] [Abstract][Full Text] [Related]
10. High anti-HLA response in women exposed to intrauterine transfusions for severe alloimmune hemolytic disease is associated with mother-child HLA triplet mismatches, high anti-D titer, and new red blood cell antibody formation. Verduin EP; Schonewille H; Brand A; Haasnoot GW; Claas FH; Lindenburg IT; Lopriore E; Oepkes D; Roelen DL; Doxiadis II Transfusion; 2013 May; 53(5):939-47. PubMed ID: 22924899 [TBL] [Abstract][Full Text] [Related]
11. Prognostic factors and management in pregnancies complicated with severe kell alloimmunization: experiences of the last 13 years. Babinszki A; Lapinski RH; Berkowitz RL Am J Perinatol; 1998; 15(12):695-701. PubMed ID: 10333397 [TBL] [Abstract][Full Text] [Related]
12. Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. Nwogu LC; Moise KJ; Klein KL; Tint H; Castillo B; Bai Y Transfusion; 2018 Mar; 58(3):677-684. PubMed ID: 29250791 [TBL] [Abstract][Full Text] [Related]
13. High-dose intravenous gamma globulin: does it have a role in the treatment of severe erythroblastosis fetalis? Chitkara U; Bussel J; Alvarez M; Lynch L; Meisel RL; Berkowitz RL Obstet Gynecol; 1990 Oct; 76(4):703-8. PubMed ID: 2120641 [TBL] [Abstract][Full Text] [Related]
14. [Foetal-maternal alloimmunizations in the South-East area of the Venice province]. Gessoni G; Valverde S; Giacomini A; Antico F; Salvadego M; Arreghini N; De Fusco G; Fezzi M; Marchiori G; Manoni F Minerva Ginecol; 2002 Aug; 54(4):333-8. PubMed ID: 12114866 [TBL] [Abstract][Full Text] [Related]
15. Predicting Intrauterine Transfusion Interval and Perinatal Outcomes in Alloimmunized Pregnancies: Time-to-Event Survival Analysis. Snelgrove JW; D'Souza R; Seaward PGR; Windrim R; Kelly EN; Ryan G Fetal Diagn Ther; 2019; 46(6):425-432. PubMed ID: 31195389 [TBL] [Abstract][Full Text] [Related]
16. Obstetric history and antibody titer in estimating severity of Kell alloimmunization in pregnancy. van Wamelen DJ; Klumper FJ; de Haas M; Meerman RH; van Kamp IL; Oepkes D Obstet Gynecol; 2007 May; 109(5):1093-8. PubMed ID: 17470588 [TBL] [Abstract][Full Text] [Related]
17. Postnatal outcome in neonates with severe Rhesus c compared to rhesus D hemolytic disease. Rath ME; Smits-Wintjens VE; Lindenburg IT; Folman CC; Brand A; van Kamp IL; Oepkes D; Walther FJ; Lopriore E Transfusion; 2013 Jul; 53(7):1580-5. PubMed ID: 23113703 [TBL] [Abstract][Full Text] [Related]